Is oxytocin receptor antagonist administration around embryo transfer associated with IVF treatment success? A systematic review and meta-analysis.

Published
October 24, 2021
Journal
Reproductive biomedicine online
PICOID
19353442
DOI
Citations
3
Keywords
Atosiban, Barusiban, IVF, Nolasiban, Oxytocin receptor antagonist, Uterine contractions
Copyright
Copyright © 2021. Published by Elsevier Ltd.
Patients/Population/Participants

women undergoing IVF treatment

Intervention

administration of an oxytocin receptor antagonist (OTR-a) around embryo transfer

Comparison

administration of placebo/nil

Outcome

live birth and pregnancy achievement

Abstract

P
I
C
O

A systematic literature review and meta-analysis was conducted to evaluate whether the administration of an oxytocin receptor antagonist (OTR-a) around embryo transfer is associated with live birth and pregnancy achievement in IVF treatment. Multiple databases were searched for randomized controlled trials (RCT) comparing the outcome of IVF treatment with administration of an OTR-a before, during or after embryo transfer versus administration of placebo/nil. The literature search identified 11 eligible RCT. The active compound was intravenous atosiban (n = 7), subcutaneous barusiban (n = 1) and oral nolasiban (n = 3). Clinical pregnancy rate was significantly higher in women receiving an OTR-a around embryo transfer (relative risk [RR] 1.31, 95% confidence interval [CI] 1.13-1.51, P = 0.0002, I

Similar article map

CEO: Hwi-yeol YunCOO: Jung-woo ChaeCTO: Sangkeun Jung
Location: 204, W6, Chungnam National University, 99, Daehak-ro, Yuseong-gu, Daejeon, Republic of Korea
Tel: 042-821-7328E-mail: webmaster@lilac-co.kr
Copyright © 2024 by LiLac. All Rights Reserved.